Success Stories

NIH Public Access


Manuscript A, Leads PD
Tuberculosis - vol. 89 331-333 (2010)

Biochimie Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding


Dos S, Pang Y, Vishnu N, Voisset C, Galons H, Blondel M, Sanyal S
Biochimie - vol. 93 1047-1054 (2011)

Are pyridazines privileged structures?


Wermuth CG
MedChemComm - vol. 2 935 (2011)

One can estimate that about 50% of all the drug molecules used in medicine contain a phenyl ring which can be substituted or not. The bioisosteric replacement of these phenyl rings by the corresponding pyridazine rings opens an access to several thousands of diaza analogues presenting more interaction possibilities, lower Log P values and improved […]

P.4.11 Developing therapies for congenital myopathies by high throughput chemical screening in ryanodine receptor 1 mutant zebrafish

Neuromuscular Disorders

Gupta V, Kuwada J, Beggs A
Neuromuscular Disorders - vol. 23 762-763 (2013)

Label-Free Quantitative Mass Spectrometry Reveals Novel Pathways Involved in LL-37 Expression

Journal of Innate Immunity

Cederlund A, Nylén F, Miraglia E, Bergman P, Gudmundsson GH, Agerberth B
Journal of Innate Immunity 365-376 (2013)

Structure − Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost α 2- Adrenergic Receptor Agonistic Activity

ACS Chem. Neurosci. 2014,

Nguyen P, Hammoud H, Halliez S, Pang Y, Evrard J, Blondel M, Strasbourg UD, De F
ACS Chem. Neurosci. 2014, - vol. 5 1075-1082 (2014)

Phenotypic Screens Targeting Neurodegenerative Diseases

Journal of Biomolecular Screening

Zhang M, Luo G, Zhou Y, Wang S, Zhong Z
Journal of Biomolecular Screening - vol. 19 1-16 (2014)

Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation

Cancer Immunology, Immunotherapy

Theorell J, Gustavsson AL, Tesi B, Sigmundsson K, Ljunggren HG, Lundbäck T, Bryceson YT
Cancer Immunology, Immunotherapy - vol. 63 627-641 (2014)

A screening cascade to identify ERβ ligands

Nuclear Receptor Signaling

Filgueira CS, Benod C, Lou X, Gunamalai PS, Villagomez RA, Strom A, Gustafsson J, Berkenstam AL, Webb P
Nuclear Receptor Signaling - vol. 12 1-13 (2014)

The establishment of effective high throughput screening cascades to identify nuclear receptor (NR) ligands that will trigger defined, therapeutically useful sets of NR activities is of considerable importance. Repositioning of existing approved drugs with known side effect profiles can provide advantages because de novo drug design suffers from high developmental failure rates and undesirable side […]

Development of A Cell-Based Assay to Identify Small Molecule Inhibitors of FGF23 Signaling

ASSAY and Drug Development Technologies

Diener S, Schorpp K, Strom T, Hadian K, Lorenz-Depiereux B
ASSAY and Drug Development Technologies - vol. 13 476-487 (2015)

Abstract Fibroblast growth factor 23 (FGF23) is a bone-derived endocrine key regulator of phosphate homeostasis. It inhibits renal tubular phosphate reabsorption by activating receptor complexes composed of FGF receptor 1c (FGFR1c) and the co-receptor Klotho. As a major signaling pathway mitogen-activated protein kinase (MAPK) pathway is employed. In this study, we established an FGF23-inducible cell […]